Topic: non-Hodgkin lymphoma
Longtime Cowen analyst Eric Schmidt is joining Arie Belldegrun's latest CAR-T startup, Allogene.
Epizyme's lead asset tazemetostat posted promising interim data from a phase 2 trial in follicular lymphoma.
Just 48 hours after filing a $115 million IPO, Forty Seven unveiled the first data for its CD47 antibody at ASCO, pledging moves into phase 2 studies.
Unum revealed more than its IPO goals in its SEC filing: a clinical hold and two patient deaths.
Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.
Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
Scientists at Pfizer have figured out how to make blood cancer cells more vulnerable to attack—by driving them from their favorite hiding place.